> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letter
- URL: https://www.fdaweb.com/latest-fda-warning-letter-19/
- Published: 2018-08-28T12:00:00.000Z
- Updated: 2026-09-15T00:28:24.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142220

FDA has posted its latest batch of Warning Letters that includes one medical product company. It can be accessed by clicking on the link following the summary below:

**Kelley-Ross Compounding** Seattle, WA (7/30): FDA inspected the firm 7/2017 and cited it for serious deficiencies in its practices for producing sterile drug products. During the inspection, FDA investigators noted that drug products produced by the firm failed to meet drug compounding exemptions. For example, the agency noted that the firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products it produced. FDA investigators also noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions.

[https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm618434.htm](https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm618434.htm?ref=fdaweb.com)